Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

C4 Therapeutics (CCCC) Operating Expenses (2019 - 2025)

Historic Operating Expenses for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to $45.6 million.

  • C4 Therapeutics' Operating Expenses rose 466.91% to $45.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $159.9 million, marking a year-over-year increase of 450.59%. This contributed to the annual value of $155.2 million for FY2024, which is 287.19% down from last year.
  • Latest data reveals that C4 Therapeutics reported Operating Expenses of $45.6 million as of Q3 2025, which was up 466.91% from $35.0 million recorded in Q2 2025.
  • C4 Therapeutics' 5-year Operating Expenses high stood at $45.6 million for Q3 2025, and its period low was $27.9 million during Q1 2021.
  • Over the past 5 years, C4 Therapeutics' median Operating Expenses value was $39.0 million (recorded in 2022), while the average stood at $37.9 million.
  • Per our database at Business Quant, C4 Therapeutics' Operating Expenses skyrocketed by 5537.53% in 2021 and then tumbled by 1686.22% in 2024.
  • Over the past 5 years, C4 Therapeutics' Operating Expenses (Quarter) stood at $35.3 million in 2021, then increased by 16.45% to $41.1 million in 2022, then dropped by 1.12% to $40.7 million in 2023, then rose by 5.4% to $42.9 million in 2024, then grew by 6.43% to $45.6 million in 2025.
  • Its Operating Expenses stands at $45.6 million for Q3 2025, versus $35.0 million for Q2 2025 and $36.4 million for Q1 2025.